Veracyte, Inc.

Veracyte is a global molecular diagnostics company specializing in genomic testing for cancer diagnosis, risk stratification, and treatment guidance. Founded in 2006 and headquartered in South San Francisco with operations in Austin, Texas, and Haifa, Israel, the company has impacted over 800,000 patients through its evidence-based portfolio of gene expression and genomic sequencing classifiers. Veracyte's core platform integrates transcriptomics, genomics, AI-assisted bioinformatics, and clinical outcome data to deliver actionable insights for thyroid, prostate, breast, bladder, and lung cancers. Key validated tests include Afirma (thyroid nodule classification), Decipher (prostate and bladder genomic assessment), and Prosigna (breast cancer risk of recurrence). The company's diagnostic innovation engine supports both LDT laboratory developed tests and collaborative R&D with biopharmaceutical partners, backed by >600 peer-reviewed publications and >35 prospective clinical trials.